Saudi Chemical Holding (2230) Fair Value & Analysis
Healthcare · SA · Market cap 6.9B SAR
Fair value as of: Aug 5, 2026
From 26 valuation models · updated 5 days ago
Share price +1.4% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (5.48 SAR to 9.98 SAR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.
How to read this chart
60‑month range 1.82 SAR – 11.83 SAR · fair‑value band 5.48 SAR – 9.98 SAR · the 8.19 SAR price screens above the 7.73 SAR fair value. Dashed = 300-day average. As of Aug 5, 2026.
Analysis
Saudi Chemical Holding (2230) currently trades at 8.19 SAR, while our model-based Fair Value estimate is 7.73 SAR, implying the stock looks roughly 5.6% fairly valued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Saudi Chemical Holding generated revenue of 7.0B SAR at a net margin of 4.9%. Revenue grew 5.0% year over year. It earns a return on equity of 14.7%. Net debt stands at 1.1B SAR. Fundamentals as of Aug 5, 2026
Our scenario range runs from 5.48 SAR (bear case) to 9.98 SAR (bull case); at 8.19 SAR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 37% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -6%, 2230 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (9.53 SAR) versus Dividend Discount (0.7600 SAR). Highest evidence: Growth DCF (80).
Notify me when 2230 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Saudi Chemical Holding Company engages in the manufacture, distribution, and retail of medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools and equipment, supplies of hospitals and medical centers and its related spare parts, and food products.
Full company description
Saudi Chemical Holding Company engages in the manufacture, distribution, and retail of medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools and equipment, supplies of hospitals and medical centers and its related spare parts, and food products. The company operates through three segments: Explosives; Medicine and Medical Supplies; and Production of Ammonium Nitrate. It also manufactures and sells explosives and related products for civilian and military use; provides technical support services in explosions; and the manufacture of ammonium nitrate. In addition, the company engages in the wholesale and retail trade of cosmetics, perfumes, beauty soups, and other supplies; and packaging and storing of medicines and other medical products. Further, it manages, invests funds, and owning real estate; provides loans and guarantees, and financing, as well as owning industrial rights. It operates in the Kingdom of Saudi Arabia and internationally. The company was founded in 1972 and is based in Riyadh, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Saudi Chemical Holding reported revenue of 6.9B SAR in FY2025 versus 3.4B SAR in FY2021, a compound +19.2%/yr. Reported net income was 335M SAR in FY2025, compounding +48.2%/yr from FY2021.
of which total revenue +11.1 pp · buybacks/dilution −4.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 2230: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Saudi Chemical Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Saudi Chemical Holding (2230) overvalued or undervalued?
What is the fair value of 2230?
What is the quality score of 2230?
What is the revenue of Saudi Chemical Holding (2230)?
What is the net profit margin of 2230?
Does Saudi Chemical Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Saudi Chemical Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.